Zynerba Pharmaceuticals, Inc. appointed Warren Cooper as a Lead Independent Director. In this role, Dr. Cooper, who has served as one of Zynerba's independent directors since August 2015, will act as a key liaison between the Chairman and the independent directors, among other responsibilities Dr. Cooper is a UK-trained physician with more than 35 years of experience in the global pharmaceutical industry. Previously, Dr. Cooper was the CEO of Prism Pharmaceuticals, a venture-backed, specialty pharmaceutical company that he led from inception in September 2004 until the sale of the Company to Baxter International in May 2011.
Zynerba Pharmaceuticals, Inc.
Equities
ZYNE
US98986X1090
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |